BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28664935)

  • 21. Molecular and clinicopathologic characterization of pediatric histiocytoses.
    Hélias-Rodzewicz Z; Donadieu J; Terrones N; Barkaoui MA; Lambilliotte A; Moshous D; Thomas C; Azarnoush S; Pasquet M; Mansuy L; Aladjidi N; Jeziorski E; Marec-Berard P; Gilibert-Yvert M; Spiegel A; Saultier P; Pellier I; Pagnier A; Pertuisel S; Poiree M; Bodet D; Millot F; Isfan F; Stephan JL; Leruste A; Rigaud C; Filhon B; Carausu L; Reguerre Y; Kieffer I; Brichard B; Ben Jannet R; Bakari M; Idbaih A; Bodemer C; Cohen-Aubart F; Haroche J; Tazi A; Boudjemaa S; Fraitag S; Emile JF; Heritier S;
    Am J Hematol; 2023 Jul; 98(7):1058-1069. PubMed ID: 37115038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutation leading to central nervous system rosai-dorfman disease.
    Richardson TE; Wachsmann M; Oliver D; Abedin Z; Ye D; Burns DK; Raisanen JM; Greenberg BM; Hatanpaa KJ
    Ann Neurol; 2018 Jul; 84(1):147-152. PubMed ID: 30014527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.
    Goyal G; Ravindran A; Young JR; Shah MV; Bennani NN; Patnaik MM; Nowakowski GS; Thanarajasingam G; Habermann TM; Vassallo R; Sher T; Parikh SA; Rech KL; Go RS;
    Haematologica; 2020; 105(2):348-357. PubMed ID: 31004029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: possible relationship of two histiocytic disorders in rare cases.
    O'Malley DP; Duong A; Barry TS; Chen S; Hibbard MK; Ferry JA; Hasserjian RP; Thompson MA; Richardson MS; Jaffe R; Sidhu JS; Banks PM
    Mod Pathol; 2010 Dec; 23(12):1616-23. PubMed ID: 20729813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
    Geerlinks AV; Abla O
    Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous Rosai Dorfman disease harboring RET and MAP2K1 mutations, successfully treated with methotrexate.
    Konstantinou MP; Tournier E
    Int J Dermatol; 2022 Nov; 61(11):1409-1411. PubMed ID: 35569068
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinicopathological and Gene Mutation Analysis of 27 Cases with Extranodal Rosai-Dorfman Disease.
    Tang M; Gu XZ; Wu PC; Yang XT
    J Inflamm Res; 2022; 15():2775-2787. PubMed ID: 35518839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease.
    Baraban E; Sadigh S; Rosenbaum J; Van Arnam J; Bogusz AM; Mehr C; Bagg A
    Br J Haematol; 2019 Sep; 186(6):837-844. PubMed ID: 31172509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosai-Dorfman Disease between Proliferation and Neoplasia.
    Elbaz Younes I; Sokol L; Zhang L
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status.
    Abeykoon JP; Rech KL; Young JR; Ravindran A; Ruan GJ; Dasari S; Morlote DM; King RL; Rummage C; Zanwar S; Acosta-Medina AM; Tobin WO; Shah MV; Bennani NN; Vassallo R; Ryu JH; Koster MJ; Davidge-Pitts CJ; Witzig TE; Goyal G; Go RS;
    JAMA Oncol; 2022 Dec; 8(12):1816-1820. PubMed ID: 36201194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z; Bilalovic N; Palazzo JP; Bender RP; Swensen J; Millis SZ; Vranic S; Von Hoff D; Arceci RJ
    Oncotarget; 2015 Aug; 6(23):19819-25. PubMed ID: 26110571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.
    Xerri L; Adélaïde J; Popovici C; Garnier S; Guille A; Mescam-Mancini L; Laurent C; Brousset P; Coze C; Michel G; Chaffanet M; Bouabdallah R; Coso D; Bertucci F; Birnbaum D
    Am J Surg Pathol; 2018 Feb; 42(2):150-159. PubMed ID: 29194093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.
    Wu KJ; Li SH; Liao JB; Chiou CC; Wu CS; Chen CC
    Biology (Basel); 2021 May; 10(5):. PubMed ID: 34063325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
    Haroche J; Abla O
    Hematology Am Soc Hematol Educ Program; 2015; 2015():571-8. PubMed ID: 26637774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
    Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
    Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histiocytosis.
    Rocamora-Blanch G; Climent F; Solanich X
    Med Clin (Barc); 2023 Aug; 161(4):166-175. PubMed ID: 37263840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
    Kemps PG; Hebeda KM; Pals ST; Verdijk RM; Lam KH; Bruggink AH; de Lil HS; Ruiterkamp B; de Heer K; van Laar JA; Valk PJ; Mutsaers P; Levin MD; Hogendoorn PC; van Halteren AG
    J Pathol Clin Res; 2021 Jan; 7(1):10-26. PubMed ID: 32852896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus.
    Ragotte RJ; Dhanrajani A; Pleydell-Pearce J; Del Bel KL; Tarailo-Graovac M; van Karnebeek C; Terry J; Senger C; McKinnon ML; Seear M; Prendiville JS; Tucker LB; Houghton K; Cabral DA; Guzman J; Petty RE; Brown KL; Tekano J; Wu J; Morishita KA; Turvey SE
    Clin Immunol; 2017 Feb; 175():143-146. PubMed ID: 28043923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosai-Dorfman Disease of the Rectum: Newly Identified Genetic Point Mutations and Robotic Resection.
    Lambdin J; Phillips JK; Kima ED; Paal E; Nava VE; Duncan J
    Am Surg; 2023 Jun; 89(6):2897-2899. PubMed ID: 35187965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.